Treatment of Infantile Hemangioma

Introduction to Treatment Guidelines

The American Academy of Pediatrics recommends that propranolol oral is the first-line treatment for infantile hemangiomas that require intervention, with a dose of 2 mg/kg/day divided into three doses, started in a clinical setting with cardiovascular monitoring 1.
The American Family Physician suggests that the majority (90%) of hemangiomas involute spontaneously without intervention by the age of 4 years 2.

Indications for Active Treatment

The American Family Physician indicates that treatment is recommended in situations where there are life-threatening conditions (heart failure, respiratory difficulty) 3, 4.
The American Family Physician also recommends treatment for functional compromise (visual obstruction, feeding problems, ptosis, amblyopia, astigmatism) 4.
Pain or active bleeding is another indication for treatment, as per the American Family Physician 5.
Ulceration is a common complication that requires treatment, according to the Pediatrics journal 6.
The risk of permanent disfigurement, especially facial lesions, is another indication for treatment, as suggested by the American Family Physician 5.

Treatment Algorithm

Asymptomatic and Non-Problematic Hemangiomas

Observation without treatment is the appropriate management, with regular monitoring to assess growth and potential complications, as recommended by the American Family Physician 5, 2.

Hemangiomas Requiring Intervention

First-Line Medical Therapy: Oral Propranolol

The dose of propranolol is 2 mg/kg/day divided into three doses, as recommended by the American Family Physician 1, 2.
The American Family Physician suggests that propranolol should be started in a clinical setting with cardiovascular monitoring every hour for the first 2 hours 1.
Special considerations include initiating propranolol as an inpatient in infants under 8 weeks, postconceptional age under 48 weeks, or presence of risk factors, as recommended by the American Family Physician 1.
The efficacy of propranolol is a rapid reduction in hemangioma size, with progressive improvement over at least 3 months, as reported in the Pediatrics journal 6.
The failure rate of propranolol is approximately 1.6%, according to the Pediatrics journal 6.

Alternative Medical Therapy: Corticosteroids

The American Family Physician recommends that systemic corticosteroids are an alternative when propranolol cannot be used or is ineffective 1.
The dose of prednisolone or prednisone is 2-3 mg/kg/day as a single morning dose, as suggested by the American Family Physician 1.
The duration of corticosteroid therapy is frequently several months, as recommended by the American Family Physician 1.
The efficacy of corticosteroids is higher when started during the proliferative phase, according to the American Family Physician 1.

Surgical Management

The American Family Physician recommends that surgical resection should generally be delayed until after infancy to allow for natural involution and better outcomes 1, 5, 2.
The optimal time for surgical resection is before the age of 4 years, as most hemangiomas do not improve significantly after this age, as suggested by the American Family Physician 1, 2.
The risk of surgical resection in infancy includes higher risk of anesthetic morbidity, blood loss, and iatrogenic injury, according to the American Family Physician 2.

Laser Therapy

The American Family Physician recommends that laser therapy may be useful in specific situations, such as early hemangioma, focal lesion in a favorable location, or elective surgery where the scar would be the same if removed after involution 1, 5, 7.
The laser of choice for superficial hemangiomas is the pulsed dye laser (PDL), as reported in the Pediatrics journal 6.
The Nd:YAG laser is the treatment of choice for hemangiomas with subcutaneous components, according to the American Family Physician 1.

Special Considerations by Location

Periocular Hemangiomas

The American Family Physician recommends that periocular hemangiomas require early evaluation by a pediatric ophthalmologist to prevent astigmatism, strabismus, or amblyopia 2.
Propranolol is preferred over intralesional steroids due to the risk of retinal artery embolization, as suggested by the American Family Physician 2.

Hepatic Hemangiomas

The American Family Physician recommends that small to medium-sized hepatic hemangiomas (<5 cm) can be managed conservatively with observation 5.
Large hepatic hemangiomas (>5 cm) require increased monitoring due to a higher risk of complications (rupture approximately 3.2%, increasing to 5% for lesions >10 cm), as reported in the American Family Physician 5.
Infants with cutaneous hemangiomas should be screened for hepatic lesions with ultrasonography, according to the American Family Physician 2.

Vertebral Hemangiomas

The American Family Physician recommends that asymptomatic vertebral hemangiomas discovered incidentally do not require treatment or routine surveillance 7.
These are distinct from infantile cutaneous hemangiomas: they do not involute spontaneously, and propranolol has no role in their management, as reported in the American Family Physician 7.

Additional Evaluations Necessary

The American Family Physician recommends that multifocal or significantly diffuse hemangiomas require screening for thyroid hormone, as the tumor may inactivate thyroid hormone 2.
Evaluation for structural anomalies is necessary in patients who require intervention, as suggested by the American Family Physician 4.
Ultrasonography is the preferred initial imaging modality when indicated, according to the American Family Physician 4, 5.

When to Refer

The American Family Physician recommends that referral to a specialist or multidisciplinary vascular anomalies center is recommended when complications are likely or the threshold for intervention is uncertain 2.

Flash Filling Hemangioma Management

Diagnostic Approach

The American College of Radiology recommends observation without intervention for small hepatic hemangiomas showing rapid arterial enhancement on imaging, as these are benign vascular lesions that rarely cause complications 8
Contrast-enhanced ultrasound (CEUS) can provide definitive diagnosis in 77-93% of indeterminate liver lesions, with a typical CEUS pattern showing peripheral nodular enhancement in arterial phase with centripetal filling over 1-5 minutes, eventually becoming isoechoic in late phase 9
The American Academy of Pediatrics suggests that clinical diagnosis is usually sufficient for infantile hemangiomas, and imaging is only indicated if diagnosis is uncertain, or anatomic abnormalities are suspected 10
Ultrasonography with Doppler is the initial imaging modality of choice for infantile hemangiomas when needed, with no sedation required and no radiation exposure 10, 11

Treatment Approach

The American Academy of Pediatrics recommends oral propranolol 2 mg/kg/day divided into three doses as first-line treatment for infantile hemangiomas requiring intervention, initiated in a clinical setting with cardiovascular monitoring 10
The American College of Radiology suggests that MRI with contrast is reserved for deep facial structures, periorbital/intraorbital extent, or lumbosacral lesions with potential spinal involvement 11, 12
The Clinical and Molecular Hepatology journal notes that multiple cutaneous hemangiomas (≥5) require screening for hepatic involvement with ultrasonography, and evaluation of thyroid function 9

Risk Stratification

The American Academy of Pediatrics identifies high-risk hemangiomas requiring prompt specialist referral, including life-threatening complications, functional impairment, segmental facial/scalp hemangiomas, and large facial lesions (>4 cm or risk of permanent disfigurement) 10
The Clinical and Molecular Hepatology journal notes that the presence of ≥5 hemangiomas is a risk factor for hepatic involvement 9

Management of Infantile Hemangioma

Risk Stratification and Treatment

Lip and perineal hemangiomas have a higher risk of ulceration, especially segmental lesions, and early pharmacotherapy with propranolol may prevent ulceration, according to the American Academy of Pediatrics 13
Infants with significant multifocal or diffuse hemangiomas require thyroid hormone screening, as the tumor can deactivate thyroid hormone, and hormone replacement may be necessary, as recommended by the American Academy of Pediatrics 13

Diagnostic Imaging

MRI with contrast is reserved for deep facial structures, periorbital/intraorbital extent, or lumbosacral lesions with potential spinal involvement, as suggested by the American College of Radiology 14
Ultrasonography is not the only preferred initial imaging modality mentioned, however MRI with contrast is also suggested for certain cases, with a strength of evidence not provided, by the American College of Radiology 15

Referral and Management

Refer to a specialist or multidisciplinary vascular anomaly center when complications are likely or already present, or when the threshold for intervention is uncertain, according to the American Academy of Pediatrics 13

Referral and Workup for Large Scalp Infantile Hemangioma

Primary Specialist Referral

The British Society for Paediatric Dermatology recommends that infants with large scalp hemangiomas be referred first to a pediatric dermatologist, who is specifically trained to initiate and supervise oral propranolol therapy; dosing regimens should be determined by the supervising dermatologist or pediatrician. 16
When a segmental scalp hemangioma is present, the British Society for Paediatric Dermatology advises that a pediatric cardiologist perform echocardiography and electrocardiography before starting full‑dose propranolol as part of PHACES syndrome screening. 17

Risks Specific to Scalp Location

Scalp hemangiomas carry a higher risk of disfigurement, especially when the lesion distorts anatomical landmarks, warranting early specialist evaluation. 16

PHACES Syndrome Screening

Segmental facial or scalp hemangiomas mandate screening for PHACES syndrome (posterior fossa malformations, arterial anomalies, cardiac defects, eye abnormalities) according to the British Society for Paediatric Dermatology. 16
Brain MRI/MRA should be obtained before full‑dose propranolol in patients with segmental head‑and‑neck hemangiomas; any identified arterial stenosis or agenesis should be reviewed with a pediatric neurologist to guide treatment decisions. 17

Multidisciplinary Specialist Involvement

The American Academy of Pediatrics lists large cutaneous vascular lesions (including extensive scalp hemangiomas) as indications for referral to a pediatric plastic surgeon for assessment of potential future disfigurement and reconstruction planning. 18
Pediatric neurologists should be consulted when neuroimaging reveals vascular anomalies, to discuss propranolol dosing and monitoring. 17

Practical Referral Guidelines

The British Society for Paediatric Dermatology cautions against referring infants with large scalp hemangiomas to general surgery or adult dermatology, as pediatric subspecialty expertise is required for safe propranolol initiation and cardiovascular monitoring. 16
Failure to perform PHACES syndrome screening (cardiac and neurologic evaluation) before full‑dose propranolol is a recognized pitfall and should be avoided. 17

Documentation and Initial Assessment

Clinical photographs of the lesion should be taken at presentation to establish a baseline for future comparison, as recommended by the British Society for Paediatric Dermatology. 17
Determination of lesion morphology (segmental versus focal) is essential because segmental lesions alter the required workup, including cardiac and neuroimaging assessments. 16

Management of Periocular Infantile Hemangioma in Newborns

Risk Stratification

Periocular hemangiomas pose a high risk of amblyopia, astigmatism, and strabismus regardless of their initial size. [19][20]
The most rapid proliferative growth occurs between 1–3 months of age, with overall growth usually completing by 5 months. 21
Visual‑axis obstruction, even if partial, can lead to deprivation amblyopia, making early ophthalmologic evaluation essential. 19
Functional visual impairment (e.g., ptosis, strabismus, abnormal red reflex) is an urgent indication for treatment. [19][20]

Initial Assessment and Referral

All infants with a periocular hemangioma should be referred to a pediatric ophthalmologist by 1 month of age for baseline evaluation, even when the lesion appears very small. 21
Weekly monitoring during the first 3 months is recommended while the lesion is in its most rapid growth phase. 21

Monitoring Protocol for Uncomplicated Lesions

During the proliferative phase (first 5 months), infants should be examined every 2–4 weeks to detect visual‑axis obstruction, ptosis, rapid growth, or ulceration. [21][19]20
The majority of hemangiomas that will cause visual problems become evident by 3 months of age. 21

Indications for Active Treatment

Visual‑axis obstruction (even partial) 19
Ptosis causing occlusion 20
Rapid growth threatening visual function 20
Ulceration with pain or bleeding 19

First‑Line Pharmacologic Therapy

Oral propranolol is the preferred first‑line agent, dosed at 2–3 mg/kg/day divided into three doses. 21
Initiation must occur in a clinical setting with cardiovascular monitoring for the first 2 hours to ensure safety. [22][21]
The typical treatment course lasts 6–12 months. 21

Critical Timing Considerations

Delaying ophthalmology referral can result in irreversible amblyopia if visual development is disrupted during the first year of life. [19][21]
Assuming that a very small lesion is low‑risk is incorrect; the periocular location alone confers high complication risk. 20
Waiting beyond 5 months of age may miss the optimal window to prevent permanent visual sequelae. 21

Mandatory Referral Triggers

Any periocular hemangioma, irrespective of size, warrants immediate specialist referral. 21
Presence of visual‑impairment signs (ptosis, strabismus, abnormal red reflex). 19
Rapid lesion growth during the proliferative phase. 20
Parental concern regarding vision or appearance. 19

Summary Principle

The periocular location makes even a “very small” hemangioma potentially high‑risk; early specialist evaluation is essential to prevent permanent visual disability. [19][21]

Management of Infantile and Hepatic Hemangiomas

First‑Line Pharmacologic Therapy

Oral propranolol at a dose of 2–3 mg/kg/day divided into three doses is the recommended first‑line treatment for infantile hemangiomas that require intervention; initiation must occur in a clinical setting with cardiovascular monitoring. 23

Indications for Treatment (Risk Stratification)

Treatment is mandatory for hemangiomas that cause life‑threatening complications such as airway obstruction (subglottic hemangioma with biphasic stridor), high‑output cardiac failure from hepatic lesions, or severe hypothyroidism from diffuse hepatic involvement. 23
Hemangiomas that produce functional impairment—including visual‑axis obstruction, feeding difficulties, or compromised hand function—should be treated. 23
Lesions located in high‑risk sites (lips, perineum, neck, scalp, intertriginous areas) have a heightened risk of ulceration and therefore warrant early therapy. 23
Large facial hemangiomas larger than 4 cm or those that distort anatomic landmarks pose a risk of permanent disfigurement and should be managed actively. 23
Segmental facial or scalp hemangiomas are associated with structural anomalies (PHACE syndrome) and require screening for posterior fossa malformations, arterial anomalies, cardiac defects, and eye abnormalities before definitive treatment. 23

Surgical and Laser Interventions

Surgical resection is generally postponed until after infancy; the optimal window for elective removal is before age 4 years, when further involution is unlikely to produce significant improvement. [24][25]
Early surgery is indicated when propranolol is contraindicated or ineffective, when the lesion is focal and situated in an anatomically favorable area, when future resection is anticipated, or when severe ulceration is unresponsive to medical therapy. 24
Pulsed‑dye laser (PDL) is recommended for residual telangiectasias or flat residual tissue after involution; its use during the proliferative phase is limited because of ulceration risk. Complications of PDL include atrophic scarring and hypopigmentation, especially in patients with darker skin tones. 24

Location‑Specific Management

For periocular hemangiomas, oral propranolol is preferred over intralesional steroids because intralesional steroids carry a risk of retinal artery embolization. 25
Facial “beard‑distribution” hemangiomas (lower face/neck) are strongly associated with subglottic airway involvement; symptomatic lesions are treated with propranolol, and non‑responders may require airway dilation, intralesional steroids, or partial surgical resection. [23][25]
Lip and perineal hemangiomas have a higher propensity for ulceration; early initiation of propranolol can prevent ulcer formation, and adjunctive topical barrier dressings reduce friction‑related ulceration in perineal lesions. 25

Screening and Monitoring Recommendations

Infants presenting with five or more cutaneous hemangiomas should undergo liver ultrasonography; approximately 8.3 % of these patients will have hepatic involvement. 26
Multifocal hepatic hemangiomas are the most common hepatic presentation, are usually asymptomatic, and tend to regress spontaneously over time. [23][26]
Diffuse hepatic hemangiomas, although rare, carry a high mortality risk; they typically present before 4 months of age with severe hepatomegaly, possible abdominal compartment syndrome, cardiac failure from macrovascular shunting, and consumptive hypothyroidism. 23
Thyroid function testing is mandatory for infants with multifocal or diffuse hepatic hemangiomas to detect consumptive hypothyroidism early. [23][25]

Referral Criteria

Refer to a pediatric vascular anomalies specialist or multidisciplinary center when complications are likely or already present, when the threshold for intervention is uncertain, when segmental facial/scalp hemangiomas necessitate PHACE syndrome work‑up, or when lesions are life‑threatening or function‑threatening. [25][23]